- Home
- CHRD vs PTGX Comparison
CHRD vs PTGX Comparison
Compare CHRD & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$80.28
Company Overview
Basic Information| Metric | CHRD | PTGX |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.4B |
| IPO Year | 2010 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CHRD | PTGX |
|---|---|---|
| Price | $92.00 | $80.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $131.20 | $93.00 |
| AVG Volume (30 Days) | 659.3K | ★ 905.5K |
| Earning Date | 02-24-2026 | 02-20-2026 |
| Dividend Yield | ★ 5.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.96 | 0.72 |
| Revenue | ★ $4,850,258,000.00 | $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $288.98 |
| P/E Ratio | ★ $31.89 | $111.36 |
| Revenue Growth | ★ 9.04 | N/A |
| 52 Week Low | $79.83 | $33.70 |
| 52 Week High | $129.32 | $96.54 |
Technical Indicators
Market Signals| Indicator | CHRD | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 32.60 |
| Support Level | $87.35 | $79.18 |
| Resistance Level | $95.09 | $89.61 |
| Average True Range (ATR) | 2.86 | 2.76 |
| MACD | -0.00 | -1.22 |
| Stochastic Oscillator | 53.50 | 8.73 |
Price Performance
Historical Comparison CHRD
PTGX
About CHRD Chord Energy Corporation
Chord Energy Corp is an independent exploration and production company. The company acquires, exploits, develops, and explores crude oil, natural gas, and natural gas liquids in the Williston Basin.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.